Actinium Pharmaceuticals is to initiate a Phase ll trial of Actimab-MDS for the treatment of myelodysplastic syndrome (MDS) next year.

The proposed trial is also aimed at studying Actimab-MDS as a conditioning regimen for patients with MDS and p53 genetic mutations who will undergo a bone marrow transplant.

During the trial, patients will receive 4.0µCi/kg administered through a single infusion 12 days prior to receiving their bone marrow transplant.

Actimab-MDS is a part of Actinium’s new clinical initiative under the company’s CD33-Alpha programme, which combines the CD33 targeting ability of lintuzumab antibody with the cell-killing power of the alpha-particle-emitting radioisotope Actinium-225.

It is based on Actinium’s clinical development experience conducted on more than 100 patients and various clinical trials with Actimab-A in patients with acute myeloid leukemia (AML) and Actimab-M in patients with multiple myeloma (MM).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“There exists a compelling revenue opportunity for Actinium in the 2020-21 timeframe by launching possibly two therapies that have the potential for increasing curative outcomes from bone marrow transplants.”

Weill Cornell New-York Presbyterian Hospital Medicine professor and leukemia programme director Dr Gail Roboz will be the principal investigator for the trial, which will see the participation of MDS Clinical Research Consortium.

Actinium chairman and CEO Sandesh Seth said: “Actimab-MDS aligns perfectly with Actinium’s strengths as we have significant expertise and know in the area of bone marrow transplant as a result of our experience with our pivotal Phase lll programme, Iomab-B.

“Looking forward, we believe there exists for Actinium a compelling revenue opportunity in the 2020-2021 timeframe by launching not one but possibly two therapies that can provide safer myeloablation with the potential for increasing curative outcomes from bone marrow transplant.”

MDS is currently estimated to be prevalent in 60,000 patients in the US and 40,000 patients in the EU.